Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Fluorodeoxyglucose F18 × 90 days × Clear all

Sponsor

Conditions

Breast Neoplasms 8 Prostatic Neoplasms 3 Uterine Cervical Neoplasms 2 Thyroid Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Oropharyngeal Neoplasms 2 Neuroendocrine Tumors 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Mouth Neoplasms 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Anus Neoplasms 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Thymus Neoplasms 1 Testicular Neoplasms 1 Solid Tumor 1 Skin Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdoid Tumor 1 Rectal Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Neoplasms, Unknown Primary 1 Melanoma 1 Lymphoma, Mantle-Cell 1

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡